Selective oral MEK1/2 inhibitor pimasertib in metastatic melanoma: antitumor activity in a phase I, dose-escalation trial

Céleste Lebbé*, Antoine Italiano, Nadine Houédé, Ahmad Awada, Philippe Aftimos, Thierry Lesimple, Monica Dinulescu, Jan H. M. Schellens, Suzanne Leijen, Sylvie Rottey, Vibeke Kruse, Richard Kefford, Eric Raymond, Sandrine Faivre, Celine Pages, Carlos Gomez-Roca, Armin Schueler, Samantha Goodstal, Giorgio Massimini, Jean Pierre Delord

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Selective oral MEK1/2 inhibitor pimasertib in metastatic melanoma: antitumor activity in a phase I, dose-escalation trial'. Together they form a unique fingerprint.

Medicine & Life Sciences